Santos-Costa Quirina, Lopes Maria Manuel, Calado Marta, Azevedo-Pereira José Miguel
Host-Pathogen Interaction Unit, Research Institute for Medicines and Pharmaceutical Sciences (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal.
Instituto de Medicina Molecular (IMM), Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisboa, Portugal.
Retrovirology. 2014 Nov 25;11:99. doi: 10.1186/s12977-014-0099-3.
Human immunodeficiency virus 1 and 2 (HIV-1 and HIV-2) use cellular receptors in distinct ways. Besides a more promiscuous usage of coreceptors by HIV-2 and a more frequent detection of CD4-independent HIV-2 isolates, we have previously identified two HIV-2 isolates (HIV-2MIC97 and HIV-2MJC97) that do not use the two major HIV coreceptors: CCR5 and CXCR4. All these features suggest that in HIV-2 the Env glycoprotein subunits may have a different structural organization enabling distinct - although probably less efficient - interactions with cellular receptors.
By infectivity assays using GHOST cell line expressing CD4 and CCR8 and blocking experiments using CCR8-specific ligand, I-309, we show that efficient replication of HIV-2MIC97 and HIV-2MJC97 requires the presence of CCR8 at plasma cell membrane. Additionally, we disclosed the determinants of chemokine receptor usage at the molecular level, and deciphered the amino acids involved in the usage of CCR8 (R8 phenotype) and in the switch from CCR8 to CCR5 or to CCR5/CXCR4 usage (R5 or R5X4 phenotype). The data obtained from site-directed mutagenesis clearly indicates that the main genetic determinants of coreceptor tropism are located within the V1/V2 region of Env surface glycoprotein of these two viruses.
We conclude that a viral population able to use CCR8 and unable to infect CCR5 or CXCR4-positive cells, may exist in some HIV-2 infected individuals during an undefined time period, in the course of the asymptomatic stage of infection. This suggests that in vivo alternate molecules might contribute to HIV infection of natural target cells, at least under certain circumstances. Furthermore we provide direct and unequivocal evidence that the usage of CCR8 and the switch from R8 to R5 or R5X4 phenotype is determined by amino acids located in the base and tip of V1 and V2 loops of HIV-2 Env surface glycoprotein.
人类免疫缺陷病毒1型和2型(HIV-1和HIV-2)以不同方式利用细胞受体。除了HIV-2对共受体的使用更为广泛以及更频繁地检测到不依赖CD4的HIV-2分离株外,我们之前还鉴定出两种不使用两种主要HIV共受体CCR5和CXCR4的HIV-2分离株(HIV-2MIC97和HIV-2MJC97)。所有这些特征表明,在HIV-2中,Env糖蛋白亚基可能具有不同的结构组织,从而能够与细胞受体进行不同的——尽管可能效率较低的——相互作用。
通过使用表达CD4和CCR8的GHOST细胞系进行感染性测定以及使用CCR8特异性配体I-309进行阻断实验,我们发现HIV-2MIC97和HIV-2MJC97的有效复制需要浆细胞膜上存在CCR8。此外,我们在分子水平上揭示了趋化因子受体使用的决定因素,并破译了参与CCR8使用(R8表型)以及从CCR8转换为CCR5或CCR5/CXCR4使用(R5或R5X4表型)的氨基酸。从定点诱变获得的数据清楚地表明,共受体嗜性的主要遗传决定因素位于这两种病毒Env表面糖蛋白的V1/V2区域内。
我们得出结论,在感染的无症状阶段的某个未定义时间段内,一些HIV-2感染个体中可能存在能够使用CCR8且无法感染CCR5或CXCR4阳性细胞的病毒群体。这表明在体内,至少在某些情况下,替代分子可能有助于HIV感染天然靶细胞。此外,我们提供了直接且明确的证据,证明CCR8的使用以及从R8到R5或R5X4表型的转换是由HIV-2 Env表面糖蛋白V1和V2环的基部和顶端的氨基酸决定的。